SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Economics of Indication-Based Drug Pricing
1 references·5 citing·19 second hop
The Economics of Indication-Based Drug Pricing (2017)The Economics of Indication-Based Drug Pr…Indication-Specific Pricing for Cancer Drugs (2014)Indication-Specific Pricing f…Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland (2022)Value and Price of Multi-indi…Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Potential approaches for the …Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination (2020)Investing in Ex Ante Regulati…Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer (2018)Cost-effectiveness of Mainten…Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma (2018)Cost-Effectiveness Analysis o…Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer (2015)A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer (2017)Value-Based Pricing for Drugs (2018)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)A convenient approximation of life expectancy (the “DEALE”) (1982)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)The NBER Patent Citations Data File: Lessons, Insights and Methodological Tools (2001)Robust Inference With Multiway Clustering (2011)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Evidence-based public policy making for medicines across countries: findings and implications for the future (2021)Managed entry agreements for pharmaceuticals: the European experience (2013)Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden (2014)Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)
this work references cited by second hop

References

  • 2014Indication-Specific Pricing for Cancer Drugs128 cited

Cited by

  • 2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications75 cited
  • 2018Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma50 cited
  • 2018Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer48 cited
  • 2020Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination47 cited
  • 2022Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland46 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work